Shandong Nuomingkang Pharmaceutical Research Institute Co., Ltd.

Primary objective: In accordance with relevant bioequivalence testing regulations, eltogliflozin tablets (5 mg) manufactured by Merck Sharp & Dohme B.V. (licensed manufacturer) and Pfizer Manufacturing Deutschland GmbH (Germany) were selected as the reference formulation. Human bioequivalence studies were conducted on the test formulation eltogliflozin tablets (5 mg) manufactured by Shandong Nuohekang Pharmaceutical Co., Ltd. and provided by Shandong Nuomingkang Pharmaceutical Research Institute Co., Ltd., under both fasting and postprandial administration conditions. The study compared the absorption rate and extent of absorption of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable limits, thus evaluating the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary objective: To observe the safety of oral administration of the test formulation eltogliflozin tablets (5 mg) and the reference formulation eltogliflozin tablets (5 mg) in healthy subjects.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation utpatinib extended-release tablets (15 mg; manufactured by Shandong Novogene Pharmaceutical Co., Ltd.) and the reference formulation utpatinib extended-release tablets (Reif®; 15 mg; manufactured by AbbVie Ireland NL B.V.) in healthy adult participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To evaluate the safety of the test formulation utpatinib extended-release tablets (15 mg) and the reference formulation utpatinib extended-release tablets (Reif®, 15 mg) in healthy participants.

Main purpose of the study: According to the provisions of the relevant bioequivalence test, dapagliflozin tablets (trade name: FORXIGA®, specification: 10 mg) with AstraZeneca AB as the licensee were selected as the reference preparation, and the test preparation dapagliflozin tablets (specification: 10 mg) produced and provided by Shandong Novocon Pharmaceutical Co., Ltd. were subjected to human bioequivalence tests on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of the study: To observe the safety of oral administration of the test preparation dapagliflozin tablets (specification: 10 mg) and the reference preparation dapagliflozin tablets (trade name: FORXIGA®, specification: 10 mg) by healthy subjects.